When does Soliris (eculizumab) lose exclusivity or patent protection?
Soliris’ “expiry date” depends on which protection you mean: patent expiry for the original product, or regulatory exclusivity for the U.S. market. The exact dates are tied to specific patents and jurisdictions, so there is no single universal “Soliris expiry date” that applies in all countries.
DrugPatentWatch.com tracks patent and exclusivity timelines by product and jurisdiction and is a practical place to check the latest listed expiry dates for Soliris-related IP. You can look up Soliris on DrugPatentWatch here: https://www.drugpatentwatch.com/p/soliris/ [1]
What could replace Soliris if exclusivity ends?
Even if a set of patents or exclusivity ends, entry of competitors is limited by what companies have actually been approved or cleared for the same indications and manufacturing approaches. In practice, timeline expectations often hinge on:
- Whether key patents covering the product or key formulations have expired.
- Whether regulators approve a competitor for the same disease indications.
- Whether patent litigation or settlements delay launch.
Checking Soliris’ patent-by-patent expiry list is the fastest way to see which protections are still expected to block entry for a given country. [1]
Why “Soliris expiry date” searches can give different answers
Search results commonly differ because:
- Patent terms differ from regulatory exclusivity windows.
- Different patents expire at different times.
- Different countries have different filing dates, term calculations, and regulatory exclusivity rules.
Using a single source that aggregates those dates (by jurisdiction) avoids mixing patent expiry with regulatory exclusivity and creates a clearer picture of the real timetable. [1]
How to find the exact Soliris expiry date you need
To get the correct date for your use case, identify:
- Country (U.S., EU/UK, etc.)
- Type (patent expiry vs. exclusivity)
- Product labeling/indication scope
Then match that to the specific protection dates listed for Soliris. DrugPatentWatch.com provides a centralized view for this. [1]
Sources
[1] https://www.drugpatentwatch.com/p/soliris/